Trial site
Clinica Universitaria de Navarra
Pamplona, Navarre 31008, SpainNot linked to an institution yet
- 12running trials
- 19closed trials
The trials here
What the 31 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 17 trials
- Phase 27 trials
- Phase 1/22 trials
- Status
- Completed16 trials
- Active, not recruiting6 trials
- Recruiting4 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Withdrawn1 trial
- Lead sponsor
- Hoffmann-La Roche15 trials
- Genentech, Inc.3 trials
- PETHEMA Foundation3 trials
- Replimune, Inc.2 trials
- Daiichi Sankyo1 trial
- and 7 more
Running trials
Recruiting
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991· Phase 3· PETHEMA Foundation· Source
Contact: Ana Alfonso Piérola
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia
NCT06830733· Phase 2· Fundacion Clinic per a la Recerca Biomédica· Source
Contact: Paula Rodríguez Otero
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source
Recruiting
Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
NCT06379945· Instituto de Investigación Biomédica de Salamanca· Source
Contact: Felipe López Cardoso, PhD
Active, not recruiting
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03742297· Phase 3· PETHEMA Foundation· Source
Active, not recruiting
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592· Phase 3· Fondazione Michelangelo· Source
Active, not recruiting
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT03589222· Phase 2· PETHEMA Foundation· Source
Active, not recruiting
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348· Phase 2· Replimune, Inc.· Source
Active, not recruiting
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· Phase 3· Hoffmann-La Roche· Source
Recruiting
Thoracic Tumours Register
NCT02941458· Spanish Lung Cancer Group· Source
Contact: Ignacio Gil-Bazo, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
NCT06723288· Hoffmann-La Roche· Source
Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270· Phase 2· Replimune, Inc.· Source
Completed
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121· Phase 1· Genentech, Inc.· Source
Completed
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
NCT05258071· Phase 2· Integrative Research Laboratories AB· Source
Completed
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624· Phase 1· Hoffmann-La Roche· Source
Completed
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
NCT05151744· Phase 2· Hoffmann-La Roche· Source
Terminated
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT04963270· Phase 3· Hoffmann-La Roche· Source
Completed
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
NCT04826003· Phase 1· Hoffmann-La Roche· Source
Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· Phase 3· Hoffmann-La Roche· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· Phase 2· Daiichi Sankyo· Source
Completed
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
NCT04468607· Phase 1· Genentech, Inc.· Source
Terminated
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
NCT03869190· Phase 1/2· Hoffmann-La Roche· Source
Completed
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Source
Completed
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
NCT03708328· Phase 1· Hoffmann-La Roche· Source
Completed
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03289962· Phase 1· Genentech, Inc.· Source
Completed
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03072238· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672· Phase 3· Hoffmann-La Roche· Source
Completed
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636· Phase 3· Hoffmann-La Roche· Source
Completed
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
NCT01454297· Multiple Myeloma Research Foundation· Source
Report an error